NOTCH3 Mutations in CADASIL Alter Lipid Metabolism: Insights from Patient Plasma and In Vitro Models

Ruihua Sun1, Xiaoyi Ji1, Wenjian Hu2

  • 1Department of Neurology, Henan Provincial People's Hospital & People's Hospital of Zhengzhou University, Zhengzhou, 450003, Henan, China.

Neurochemical Research
|August 21, 2026
PubMed

Insights

NOTCH3 mutations disrupt lipid metabolism in cerebral small vessel disease (CSVD). This study found altered plasma lipids and cellular cholesterol changes in CADASIL patients, suggesting lipid dysregulation contributes to disease.

Area of Science:

  • Neuroscience
  • Genetics
  • Metabolic Disorders

Background:

  • Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a monogenic form of cerebral small vessel disease (CSVD).
  • CADASIL is caused by mutations in the NOTCH3 gene.
  • The impact of NOTCH3 mutations on lipid metabolism is not well understood.

Purpose of the Study:

  • To investigate the effects of NOTCH3 mutations on lipid metabolism in CADASIL.
  • To analyze plasma lipid profiles in CADASIL patients and controls.
  • To examine cellular lipid alterations in cells expressing wild-type or mutant NOTCH3.

Main Methods:

  • Lipidomic analysis of plasma samples from CADASIL patients and healthy controls.
  • Establishment of cell lines (293T and hCMEC/D3) expressing wild-type or mutant NOTCH3.
  • Assessment of lipid droplet accumulation, cholesterol levels, and cholesterol transporter expression.

Main Results:

  • Significant alterations in plasma lipid profiles were observed in CADASIL patients.
  • NOTCH3 mutants (R110C, R1175W, R544C) increased lipid droplet accumulation in 293T cells.
  • All NOTCH3 mutants elevated cholesterol levels in 293T cells, and R544C mutant reduced cholesterol transporter expression in hCMEC/D3 cells.

Conclusions:

  • NOTCH3 mutations are linked to disrupted cellular lipid homeostasis.
  • Lipid metabolic dysregulation may be a contributing factor in CADASIL pathogenesis.
  • Targeting lipid metabolism could offer novel therapeutic strategies for CADASIL.

Related Concept Videos

Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...